SUNDAY 19 MAY 2019, 13:45–14:45
FORUM 2

Living with debilitating endocrine disorders: A conversation on the real patient experience
Chair: Maria Fleseriu (USA)
Welcome and introduction
Maria Fleseriu (USA)
Patient-Reported Challenges: Are We Prepared to Listen? (focus acromegaly)
Susan M Webb (Spain)
The Impact of Illness: The Perception Gap Between Us (focus Carcinoid Syndrome)
Simona Glasberg (Israel)
The real impact of endocrine disease: Understanding the patient perspective
Daphne T Adelman (USA)
Moving Forward Together
Maria Fleseriu (USA)

SUNDAY 19 MAY 2019, 13:45–14:45
FORUM 1

Burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and associated comorbidities
Chair: Pascal Hou illier (France)
Welcome and introduction
Pascal Houillier (France)
Chronic h ypoPT and its impact on symptoms, comorbidities and QoL
Lars Rejnmark (Denmark)
Renal complications in the patient with hypoPT
Pascal Houillier (France)
Genetic syndromes as a cause of hypoPT: What are the unique challenges?
Maria Luisa Brandi (Italy)
Panel discussion and Q&A
Chair/All
Summary and close
Pascal Houillier (France)

SUNDAY 19 MAY 2019, 17:45–19:15
FORUM 2

The Cushing’s Collaborative: Can cross-discipline partnerships improve outcomes?
Chairs: Antoine Tabarin (France) & Elena Valassi (Spain)
How to preserve bone health?
Jacopo Chiodini (Italy)
Is there a clear path to progress in thrombosis risk reduction?
Richard Feelders (The Netherlands)
Should neurocognitive functioning be front of mind in management strategies?
Corinela Andela (The Netherlands)
Monday 20 May 2019, 13:45–14:45

FORUM 2

ACROSTUDY: A decade of treatment experience with acromegaly patients – what have we learned?
Chair: Thierry Brue (France)
Welcome and Introduction
Thierry Brue (France)
A brief history of ACROSTUDY™
Michael Buchfelder (Germany)
Key outcomes: exploring safety and treatment outcomes
Nicholas Tritos (USA)
Impact of treatment on glucose metabolism and patient-reported outcomes
Silvia Grottoli (Italy)
Summary and Q&A
Thierry Brue (France)

Monday 20 May 2019, 13:45–14:45

LUMIERE AUDITORIUM

Updates on the diagnosis and management of Adult Growth Hormone Deficiency
Chair: Philippe Chanson (France)
Opening remarks
Philippe Chanson (France)
Rationale for GH replacement in Adults with GH deficiency
Christian Strasburger (Germany)
Updates in the diagnosis and management of Adults GH Deficiency
Beverly MK Biller (USA)
Future developments in the management of AGHD
Gudmundur Johannsson (Sweden)
Closing remarks
Philippe Chanson (France)

Monday 20 May 2019, 13:45–14:45

FORUM 3

New perspectives in managing not adequately controlled hypoparathyroid patients: Lessons from clinical practice in Europe and in the US
Chair: Peter Kamenicky (France)
New perspectives for not adequately controlled hypoPT
Peter Kamenicky (France)
Working towards a consensus to define patients with not adequately controlled hypoPT
Peter Kamenicky (France)
Treating not adequately controlled hypoPT patients with complications and comorbidities
John P Bilezikian (USA)
Management of not adequately controlled hypoPT patients with impaired biochemical control and complications
Lorenz Hofbauer (Germany)
Panel discussion and Q&A
Chair/All
Summary and close
Peter Kamenicky (France)

Monday 20 May 2019, 18:00–19:30

SALLE GRATTE-CIEL 1+2+3

Theragnostics in neuroendocrine tumors: from sceptics to believers
Chairs: Eric Baudin (France), Wouter de Herder (The Netherlands) & Diego Ferone (Italy)
Should theragnostics be reserved to a subset of patients?
Eric Baudin (France)
Theragnostics as a new paradigm for all NET patients
Wouter de Herder (The Netherlands)
What should we do in our practice?
Diego Ferone (Italy)
16:30–17:00  Graves’ disease: Pathophysiology, diagnosis, outcomes

- Pathophysiology of Graves’ disease and common clinical presentation
- Laboratory diagnosis of transient hyperthyroidism with Graves’ disease

MONDAY 20 MAY 2019
09:50–10:20  Discovering thyroid stimulating immunoglobulins

- Historical perspective on TSH receptor antibody testing design
- Innovations for the detection of thyroid stimulating antibodies
- Benefits of a chimeric TSH receptor (M04)-based bridge assay